NC
KNSA icon

Nexthera Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Nexthera Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-67,692
Closed -$1.22M – 28
2019
Q1 		$1.22M Buy
+67,692
New +$1.31M 1.48% 19
2018
Q3 		– Sell
-39,180
Closed -$680K – 61
2018
Q2 		$680K Buy
+39,180
New +$709K 0.11% 41

Other funds holding KNSA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nexthera Capital's KNSA Position: Q2 2019 in Review

Nexthera Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2019, closing a stake of 67,692 shares — an estimated $1.22M sold.

Nexthera Capital first reported a position in KNSA in Q2 2018 and held it in 2 quarters. The position peaked at $1.22M in Q1 2019. 61 funds tracked by Wall St. Rank hold KNSA as of Q2 2019.

  • Nexthera Capital reported no remaining Kiniksa Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Nexthera Capital sold 67,692 Kiniksa Pharmaceuticals shares in Q2 2019, an estimated $1.22M.
  • Nexthera Capital first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Nexthera Capital's Kiniksa Pharmaceuticals position peaked at $1.22M in Q1 2019.
  • 61 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.